SNIPSNP: precision design of CRISPR/Cas9 knock-in reagents for variant correction and disease modeling
Nucleic Acids Research · 11.07.2026 · 54 (W1) · W145-W153
DOI: 10.1093/nar/gkag409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 23.06.2026. Verfasst von Kornel Labun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, 02-106 Warsaw, Poland. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing, Gene Knock-In Techniques, Software. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norges Forskningsråd, Kreftforeningen.
Abstract (Originalsprache)
We present SNIPSNP (crisprtools.org/snipsnp), a comprehensive bioinformatics pipeline for designing experiments for CRISPR-induced homology-directed repair (HDR). The tool addresses the critical challenge of Cas9 re-cleavage by simplifying the selection of “blocking” silent variants that are effective at inhibiting RNP binding upon donor-templated editing. SNIPSNP handles complex edits, including indels, and uses multi-objective optimization to balance editing efficiency with biological safety. From user-defined wild-type and desired HDR alleles, the pipeline identifies candidate guides, annotating them with integrated efficiency scores and genome-wide off-target assessments. Uniquely, SNIPSNP evaluates guide binding against the post-edit genome to determine whether the therapeutic variant alone disrupts repeated Cas9 recognition. When necessary, it introduces synonymous blocking variants, prioritizing PAM and seed regions to minimize re-cleavage probability and editing of the wild-type (WT) allele when editing heterozygous variants. All candidate modifications undergo safety profiling and prioritization of known benign variants from dbSNP. We experimentally validated SNIPSNP and benchmarked it on pathogenic inborn error of immunity variants in primary patient T-cells. Across loci, SNIPSNP-designed templates outperform standard “correction-only” strategies, demonstrating enhanced precision editing, and reduced re-cleavage, establishing SNIPSNP as a robust platform for genome editing and disease modeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, 02-106 Warsaw, Poland.
- Computational Biology Unit, Department of Informatics, University of Bergen, Bergen 5006, Norway.
- Norwegian Centre for Molecular Biosciences and Medicine Norway, University of Oslo, Oslo 0349, Norway.
- Department of Pediatric Research, Oslo University Hospital, Oslo 0372, Norway.
- Department of Biosciences, University of Oslo, Oslo 0371, Norway.
- Michael Sars Centre, University of Bergen, Bergen 5006, Norway.
ORCID-Profile: Kornel Labun, Eivind Valen
Förderung
- Norges Forskningsråd
- Kreftforeningen
Zitieren
APA
Labun, K., Rio, O., Dahal-Koirala, S., Komisarczuk, A. Z., Valen, E., & Haapaniemi, E. (2026). SNIPSNP: precision design of CRISPR/Cas9 knock-in reagents for variant correction and disease modeling. Nucleic Acids Research, 54(W1), W145-W153. https://doi.org/10.1093/nar/gkag409
Vancouver
Labun K, Rio O, Dahal-Koirala S, Komisarczuk AZ, Valen E, Haapaniemi E. SNIPSNP: precision design of CRISPR/Cas9 knock-in reagents for variant correction and disease modeling. Nucleic Acids Research. 2026;54(W1):W145-W153. doi:10.1093/nar/gkag409
BibTeX
@article{Labun2026,
author = {Labun, Kornel and Rio, Oline and Dahal-Koirala, Shiva and Komisarczuk, Anna Zofia and Valen, Eivind and Haapaniemi, Emma},
title = {SNIPSNP: precision design of CRISPR/Cas9 knock-in reagents for variant correction and disease modeling},
journal = {Nucleic Acids Research},
year = {2026},
volume = {54},
number = {W1},
pages = {W145--W153},
doi = {10.1093/nar/gkag409}
}
EUVIMED